Mode
Text Size
Log in / Sign up
N/A N=184 Randomized Treatment

Hyperglycemic Profiles in Obstructive Sleep Apnea: Effects of PAP Therapy

Sleep Apnea · Diabetes

Enrolled (actual)
184
Serious AEs
0.5%
Results posted
May 2021
Primary outcome: Primary: Change in Continuous Glucose Monitoring System Standard Deviation — 0.8; 1.1 mg/dL

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
REMStar Positive Airway Pressure (Device); LifeStyle Counseling (Behavioral)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Johns Hopkins University
Primary completion
Mar 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Continuous Glucose Monitoring System Standard Deviation
0.8; 1.1
SECONDARY
Mean Difference in Systolic Blood Pressure
-7.3; 7.4
SECONDARY
Change in Endothelial Dysfunction as Assessed by the Reactive Hyperemic Index
-0.0014; 0.0024
SECONDARY
Heart Rate Variability
SECONDARY
Change in the Epworth Sleepiness Scale
-2.5; -1.3
SECONDARY
Change in Post-Pre Meal Blood Glucose Levels
-9.9; -1.3; 1.0; -6.1; -3.0; 3.7
SECONDARY
Change in Glycosylated Hemoglobin A1c Level
0.2; 0.2
SECONDARY
Continuous Glucose Monitoring System Mean Amplitude Glucose Excursion
69.5; 71.4
SECONDARY
Continuous Glucose Monitoring System Standard Deviation
38.7; 39.2
SECONDARY
Change in Continuous Glucose Monitoring System Mean Glucose
4.3; 9.5

Summary

This is a randomized control trial in people with diabetes and obstructive sleep apnea who will be randomly assigned for 3 months to PAP therapy along with healthy lifestyle and sleep education or healthy lifestyle and sleep education.

Eligibility Criteria

Inclusion Criteria

  • Type 2 diabetics
  • Age > 21 and ≤ 75 years

Exclusion Criteria

  • Inability to consent or commit to the required visits
  • Use of insulin or other injections for diabetes
  • Weight change of 10% in last six months
  • Use of oral steroids in the last six months
  • Pulmonary disease (i.e., COPD)
  • Renal or hepatic insufficiency
  • Recent MI or stroke (< 3 months)
  • Sleep-related hypoventilation
  • Obesity-hypoventilation syndrome
  • Morbid Obesity
  • Occupation as a commercial driver or operator of heavy machinery
  • Active substance use
  • Untreated thyroid disease
  • Pregnancy
  • Any history of seizures or other neurologic disease
  • Poor sleep hygiene or sleep disorder other than sleep apnea
  • Central sleep apnea
  • Variants of obstructive sleep apnea (e.g., REM-related OSA)
  • Participants not suitable for the study based on the clinical judgment
  • Use of any investigational drug within the past 30 days
  • Participating in another study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02454153). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search